JERUSALEM--(BUSINESS WIRE)--Mar. 22, 2016--
Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced the
launch of the generic equivalent to CAMPRAL®1 (acamprosate
calcium) delayed-release tablets, 333 mg, in the United States.
Acamprosate calcium delayed-release tablets are used for the maintenance
of abstinence from alcohol in patients with alcohol dependence who are
abstinent at the start of treatment. Treatment with acamprosate calcium
delayed-release tablets helps maintain abstinence from alcohol only when
used as part of a treatment program that includes counseling and support.
Teva continues its commitment to strengthening its generics business
with continued investment in newer, higher-quality generic products.
With over 375 generic medicines available, Teva has the largest
portfolio of FDA-approved generic products on the market.
Acamprosate calcium delayed-release tablets had annual sales of
approximately $14 million in the United States, according to IMS data as
of December 2015.
About Acamprosate Calcium Delayed-Release Tablets
Acamprosate calcium delayed-release tablets are indicated for the
maintenance of abstinence from alcohol in patients with alcohol
dependence who are abstinent at treatment initiation. Treatment with
acamprosate calcium delayed-release tablets should be part of a
comprehensive management program that includes psychosocial support.
The efficacy of acamprosate calcium in promoting abstinence has not been
demonstrated in subjects who have not undergone detoxification and not
achieved alcohol abstinence prior to beginning acamprosate calcium
delayed-release tablets treatment. The efficacy of acamprosate calcium
in promoting abstinence from alcohol in polysubstance abusers has not
been adequately assessed.
Important Safety Information
Acamprosate calcium is contraindicated in patients who previously have
exhibited hypersensitivity to acamprosate calcium or any of its
components. Acamprosate calcium is contraindicated in patients with
severe renal impairment (creatinine clearance of ≤ 30 mL/min). Treatment
with acamprosate calcium in patients with moderate renal impairment
(creatinine clearance of 30 to 50 mL/min) requires a dose reduction.
Adverse events of a suicidal nature (suicidal ideation, suicide
attempts, completed suicides) and depression were reported in controlled
clinical trials of acamprosate calcium. Alcohol-dependent patients,
including those patients being treated with acamprosate calcium, should
be monitored for the development of symptoms of depression or suicidal
thinking.
Use of acamprosate calcium does not eliminate or diminish withdrawal
symptoms.
Common adverse events that occurred in any acamprosate calcium treatment
group at a rate of 3% or greater and greater than the placebo group in
controlled clinical trials with spontaneously reported adverse events
are: accidental injury, asthenia, pain, anorexia, diarrhea, flatulence,
nausea, anxiety, depression, dizziness, dry mouth, insomnia,
paresthesia, pruritus and sweating.
For more information, please see the accompanying Full
Prescribing Information.
1 Campral® is a registered trademark of Merck
Sante.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading
global pharmaceutical company that delivers high-quality,
patient-centric healthcare solutions used by millions of patients every
day. Headquartered in Israel, Teva is the world’s largest generic
medicines producer, leveraging its portfolio of more than 1,000
molecules to produce a wide range of generic products in nearly every
therapeutic area. In specialty medicines, Teva has a world-leading
position in innovative treatments for disorders of the central nervous
system, including pain, as well as a strong portfolio of respiratory
products. Teva integrates its generics and specialty capabilities in its
global research and development division to create new ways of
addressing unmet patient needs by combining drug development
capabilities with devices, services and technologies. Teva's net
revenues in 2015 amounted to $19.7 billion. For more information, visit www.tevapharm.com.
Teva's Safe Harbor Statement under the U. S. Private Securities
Litigation Reform Act of 1995:
This release contains forward-looking statements, which are based on
management’s current beliefs and expectations and involve a number of
known and unknown risks and uncertainties that could cause our future
results, performance or achievements to differ significantly from the
results, performance or achievements expressed or implied by such
forward-looking statements. Important factors that could cause or
contribute to such differences include risks relating to: our ability to
develop and commercialize additional pharmaceutical products;
competition for our specialty products, especially Copaxone® (which
faces competition from orally-administered alternatives and a generic
version); our ability to consummate the acquisition of Allergan plc’s
worldwide generic pharmaceuticals business (“Actavis Generics”) and to
realize the anticipated benefits of such acquisition (and the timing of
realizing such benefits); the fact that following the consummation of
the Actavis Generics acquisition, we will be dependent to a much larger
extent than previously on our generic pharmaceutical business; potential
restrictions on our ability to engage in additional transactions or
incur additional indebtedness as a result of the substantial amount of
debt we will incur to finance the Actavis Generics acquisition; the fact
that for a period of time following the consummation of the Actavis
Generics acquisition, we will have significantly less cash on hand than
previously, which could adversely affect our ability to grow; the
possibility of material fines, penalties and other sanctions and other
adverse consequences arising out of our ongoing FCPA investigations and
related matters; our ability to achieve expected results from
investments in our pipeline of specialty and other products; our ability
to identify and successfully bid for suitable acquisition targets or
licensing opportunities, or to consummate and integrate acquisitions;
the extent to which any manufacturing or quality control problems damage
our reputation for quality production and require costly remediation;
increased government scrutiny in both the U.S. and Europe of our patent
settlement agreements; our exposure to currency fluctuations and
restrictions as well as credit risks; the effectiveness of our patents,
confidentiality agreements and other measures to protect the
intellectual property rights of our specialty medicines; the effects of
reforms in healthcare regulation and pharmaceutical pricing,
reimbursement and coverage; competition for our generic products, both
from other pharmaceutical companies and as a result of increased
governmental pricing pressures; governmental investigations into sales
and marketing practices, particularly for our specialty pharmaceutical
products; adverse effects of political or economic instability, major
hostilities or acts of terrorism on our significant worldwide
operations; interruptions in our supply chain or problems with internal
or third-party information technology systems that adversely affect our
complex manufacturing processes; significant disruptions of our
information technology systems or breaches of our data security;
competition for our specialty pharmaceutical businesses from companies
with greater resources and capabilities; the impact of continuing
consolidation of our distributors and customers; decreased opportunities
to obtain U.S. market exclusivity for significant new generic products;
potential liability in the U.S., Europe and other markets for sales of
generic products prior to a final resolution of outstanding patent
litigation; our potential exposure to product liability claims that are
not covered by insurance; any failure to recruit or retain key
personnel, or to attract additional executive and managerial talent; any
failures to comply with complex Medicare and Medicaid reporting and
payment obligations; significant impairment charges relating to
intangible assets, goodwill and property, plant and equipment; the
effects of increased leverage and our resulting reliance on access to
the capital markets; potentially significant increases in tax
liabilities; the effect on our overall effective tax rate of the
termination or expiration of governmental programs or tax benefits, or
of a change in our business; variations in patent laws that may
adversely affect our ability to manufacture our products in the most
efficient manner; environmental risks; and other factors that are
discussed in our Annual Report on Form 20-F for the year ended December
31, 2015 and in our other filings with the U.S. Securities and Exchange
Commission (the "SEC"). Forward-looking statements speak only as of the
date on which they are made and we assume no obligation to update or
revise any forward-looking statements or other information, whether as a
result of new information, future events or otherwise.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160322005622/en/
Source: Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
IR:
United States
Kevin
C. Mannix, 215-591-8912
or
United States
Ran Meir,
215-591-3033
or
Israel
Tomer Amitai, 972 (3)
926-7656
or
PR:
Israel
Iris Beck Codner, 972
(3) 926-7687
or
United States
Denise Bradley,
215-591-8974